Uniunea Europeană - română - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - virusul gripei de suprafață (hemaglutinină și neuraminidază) de tulpina a / vietnam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccinuri - imunizarea activă împotriva subtipului h5n1 al virusului gripal a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Uniunea Europeană - română - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccinuri - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Uniunea Europeană - română - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccinuri - active immunisation against h5 subtype of influenza a virus.

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - produsele imunologice pentru felidae, - pisici - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - produsele imunologice pentru felidae, - pisici - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Uniunea Europeană - română - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - (virion întreg, inactivat) care conține antigenul: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccinuri - profilaxia gripei într-o situație pandemică declarată oficial. vaccinul antigripal pandemic trebuie utilizat în conformitate cu orientările oficiale.

Uniunea Europeană - română - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - maxim trei din următoarele purificat, inactivat, febra aftoasă, boala tulpini de virus: o1 manisa ≥ 6 pd50*; o1 bfs ≥ 6 pd50*; o taiwan 3/97 ≥ 6 pd50*; a22 iraq ≥ 6 pd50*; a24 cruzeiro ≥ 6 pd50*; o turkey 14/98 ≥ 6 pd50*; asia 1 shamir ≥ 6 pd50*; sat2 saudi arabia ≥ 6 pd50*; * pd50 – 50% protecție doză la bovine așa cum este descris în ph. eur. monografie 0063. - immunologicals - pigs; cattle; sheep - imunizarea activă a bovinelor, ovinelor și porcilor de la vârsta de 2 săptămâni împotriva febrei aftoase pentru reducerea semnelor clinice.

Uniunea Europeană - română - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaccinuri pentru gripă - profilaxia gripei cauzate de virusul a (h1n1v) 2009. focetria ar trebui să fie utilizate în conformitate cu recomandările oficiale.

România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

gsk vaccines gmbh - germania - vaccin impotriva encefalitei de capuse - susp. inj. in seringa preumpluta - 1,5µg/0,5ml - vaccinuri virale vaccinuri contra encefalitei